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Abstract 
Objective 
To identify useful MRI abnormalities in the putamen for diagnosing multiple system 
atrophy. 
Methods 
Patients with multiple system atrophy (n = 15), Parkinson’s disease (n = 16), or 
progressive supranuclear palsy (n = 9) and healthy controls (n = 10) were enrolled. Using 
a visual analog scale, 4 examiners independently rated high-intensity signals along the 
lateral putamen on T2-weighted and T2*-weighted images, low-intensity signals within 
the putamen on T2-weighted and T2*-weighted images, and putaminal atrophy. Receiver 
operating characteristic analyses were performed, and the area under the receiver 
operating characteristic curve was calculated.  
Results 
For differentiating multiple system atrophy from progressive supranuclear plsy, 
Parkinson’s disease, and healthy controls, the mean area under the curve values was 
highest for low-intensity signals within the putamen on T2*-weighted images (0.797, 
0.867, 0.896, respectively). Variations in the area under the curve values among the 4 
examiners were smallest in low-intensity signals within the putamen on T2*-weighted 
images. Good inter-rater reliability was achieved for low-intensity signals within the 
putamen on T2*-weighted images and high-intensity signals along the lateral putamen on 
T2*-weighted images. 
Conclusion 
Low-intensity signals within the putamen on T2*-weighted images is the most useful 
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MRI abnormality for diagnosing multiple system atrophy. 
 
Highlights 
 Putaminal hypointensity on T2*WI shows the highest accuracy in diagnosing MSA. 
 Good agreement of ratings was achieved for putaminal hypointensity on T2*WI. 
 Putaminal hypotintensity on T2*WI is the most feasible sign to diagnose MSA. 
 
Introduction 
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder 
characterized by any combination of parkinsonian, autonomic, and cerebellar symptoms. 
The discovery of glial cytoplasmic inclusions enabled a clear definition of MSA as a 
clinicopathological entity [1, 2]. Because almost all patients with MSA develop 
autonomic dysfunction at some point during their disease course, MSA can be divided 
into two clinical subtypes: MSA with predominant cerebellar ataxia (MSA-C) and MSA 
with predominant parkinsonism (MSA-P) [3]. 
 
Early in the disease course, MSA may be clinically difficult to distinguish from other 
parkinsonian syndromes including Parkinson’s disease (PD) and progressive supranuclear 
palsy (PSP) [4, 5]. However, this distinction is important for prognostic and therapeutic 
implications.  
 
Magnetic resonance imaging (MRI) has been widely used to differentiate atypical 
parkinsonian syndromes from PD. Although MSA-P is frequently identified by evaluating 
putaminal degeneration via MRI techniques, such as T2-weighted images [6], 
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T1-weighted images [7], T2*-weighted images [8, 9], and diffusion-weighted images [10], 
which sequence is most useful for diagnosing patients with MSA-P in daily clinical 
practice is uncertain. 
 
We performed a receiver operating characteristic (ROC) analysis to determine the 
diagnostic usefulness of high-intensity signals along the lateral putamen on T2-weighted 
(T2H) and T2*-weighted (T2*H) images, low-intensity signals within the putamen on 
T2-weighted (T2L) and T2*-weighted images (T2*L), and putaminal atrophy for 
differentiating patients with MSA from those with PD or PSP and from healthy subjects. 
To assess the feasibility of our findings, 4 examiners that included an experienced 
neuroradiologist and radiologist, a resident physician, and a junior resident evaluated the 
area under the ROC curve (AUC) for each finding. In addition, the Kendall coefficient of 
concordance (W) was calculated to evaluate the reliability of ratings among the 4 
examiners. 
 
Materials and Methods 
Patients  
The study participants were 15 patients with MSA (9 patients with MSA-P, 6 patients 
with MSA-C), 16 patients with PD (8 patients with tremor-dominant type and 8 with 
akinetic-rigid type), 9 patients with PSP, and 10 control subjects. Eight of the PD patients 
had dementia, while the others did not. Informed consent was obtained from all subjects 
according to the ethical review board of our institution. This study was prospective and 
included consecutive patients who were referred to our hospital and had brain MRI 
between March 2012 and December 2012. 
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A clinical diagnosis of MSA (13 patients with probable MSA, 2 patients with possible 
MSA) was made according to the second consensus statement by Gilman et al. [3]. A PD 
diagnosis was made according to the UK Parkinson’s Disease Society Brain Bank clinical 
diagnostic criteria [11], and a PSP diagnosis (6 patients with probable PSP and 3 patients 
with possible PSP) was made according to the National Institute of Neurological 
Disorders and Stroke--Society for Progressive Supranuclear Palsy clinical criteria [12]. 
The control subjects were consecutive patients who were referred to our hospital with 
complaints of headache or dizziness and who had no neurologic abnormalities.  
 
MR Imaging Acquisition and Analysis 
Brain MR imaging was performed with a 1.5-T MR scanner (Signa Horizon; GE 
Healthcare, Milwaukee, WS). We acquired unenhanced axial T2- weighted and 
T2*-weighted images using the following parameters for T2-weighted images: fast spin 
echo sequence, repetition time of 4000 ms, echo time of 100 ms, average number as 2, 
field of view as 220 × 220 mm, matrix of 224 × 384, slice thickness of 6.0 mm, and slice 
gap of 1.0 mm. The parameters for T2*-weighted images were as follows: echoplanar 
sequence, repetition time of 5500 ms, echo time of 25 ms, average number as 2, field of 
view as 220 × 220 mm, matrix of 224 × 384, slice thickness of 6.0 mm, slice gap of 1.0 
mm. The axial sections were angled parallel to the antero-posterior commissure (AC-PC) 
line. 
 
Four examiners (A, experienced neuroradiologist; B, experienced radiologist; C, resident 
physician; and D, junior resident) blinded to the diagnosis and clinical data independently 
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evaluated T2H, T2L, T2*H, T2*L, and putaminal atrophy (Fig. 1). Because putaminal 
T2H, T2L, and atrophy on the T2-weighted images could bias interpretations of T2*H 
and T2*L, T2-weighted and T2*-weighted images were analyzed in a blinded 
randomized fashion for controlling such bias. T2H and T2*H were defined as a higher 
signal intensity than that of the adjacent insular cortex. T2L and T2*L were defined as a 
lower signal intensity than that of the adjacent white matter [7]. Putaminal atrophy was 
assessed by visual inspection, which included an evaluation of the posterolateral 
linearization of the putaminal margin [13]. 
 
We rated each finding on a 50-mm horizontal visual analog scale [left (0 mm), absolutely 
normal; middle (25 mm), equivocal; right (50 mm), absolutely abnormal]. We specified 
the level of confidence to a statement by indicating a position along a continuous line 
between the checked point and the left margin of the scale bar. This value was used as a 
marker of abnormality and for subsequent statistical analysis [7]. A longer length derived 
from evaluating the putamen bilaterally was used for further analysis. 
 
Statistical Analysis 
Statistical analysis of demographic data and visual analog scale score was performed 
using analysis of variance tests (ANOVA) with the Bonferroni correction for the multiple 
comparison tests and a 2 test for categoric data. The criterion of statistical significance 
was p < 0.05. 
We assessed the diagnostic usefulness of each putaminal finding with an ROC analysis. 
For differentiating patients with MSA from those with PD or PSP and from healthy 
controls, an AUC value of >0.9 is considered excellent; an AUC value of >0.8 is 
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considered good. 
 
The Kendall coefficient of concordance test was performed to assess the inter-rater 
reliability for the rankings of visual analog scale scores among the 4 examiners. W scores 
range between 0 and 1, with 1 signifying complete agreement. A level of ≥0.9 represented 
excellent agreement, a level of 0.8 to <0.9 represented good agreement, a level of 0.7 to 
<0.8 represented acceptable agreement, a level of 0.6 to <0.7 represented moderate 
agreement, and a level of <0.6 represented no agreement [14]. All statistical analyses 
were performed using statistical software (SPSS, version 20.0, SPSS) on Microsoft 
Windows. 
 
Results 
The demographics of the subject groups included in the study are shown in Table 1. There 
were no statistically significant differences in age and gender distribution of the subjects. 
Disease duration was significantly longer in PD than in MSA and PSP (p= 0.03 and 0.018, 
respectively). The visual analog scale score of each finding is shown in Table 2. The 
ROC analysis revealed that the mean AUC value for differentiating patients with MSA 
from those with PD was 0.726 in T2H, 0.731 in T2L, 0.585 in T2*H, 0.867 in T2*L, and 
0.728 in putaminal atrophy (Table 3). The AUC value for differentiating MSA from PSP 
was 0.618 in T2H, 0.601 in T2L, 0.597 in T2*H, 0.797 in T2*L, and 0.614 in putaminal 
atrophy (Table 3). The AUC value for differentiating MSA from healthy control subjects 
was 0.682 in T2H, 0.624 in T2L, 0.639 in T2*H, 0.896 in T2*L, and 0.696 in putaminal 
atrophy (Table 3). 
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The mean AUC value for differentiating among patients with MSA-P and those with PD 
was 0.805 in T2H, 0.775 in T2L, 0.599 in T2*H, 0.900 in T2*L, and 0.851 in putaminal 
atrophy (Table 3). For differentiating between MSA-P and PSP, the mean AUC value was 
0.735 in T2H, 0.665 in T2L, 0.594 in T2*H, 0.852 in T2*L, and 0.775 in putaminal 
atrophy (Table 3). For differentiating between MSA-P and healthy control subjects, the 
mean AUC value was 0.772 in T2H, 0.686 in T2L, 0.636 in T2*H, 0.915 in T2*L, and 
0.842 in putaminal atrophy (Table 3). 
 
Table 4 lists the Kendall coefficient of concordance among the 4 examiners and the 
associated p values for the ratings of each putaminal finding. Acceptable inter-rater 
reliability (0.8 > W > 0.7) was achieved for T2*L (W = 0.7959, p < 0.01) and T2*H (W = 
0.7696, p < 0.01). Moderate inter-rater reliability (0.7 > W > 0.6) was achieved for T2H 
(W = 0.6337, p < 0.01) and putaminal atrophy (W = 0.6516, p < 0.01), whereas the 
reliability for T2L was poor (W = 0.4950, p < 0.01). 
 
Discussion 
The aim of our study was to compare the usefulness of putaminal signs on T2- and 
T2*-weighted images for differentiating patients with MSA from those with PD or PSP 
and from healthy controls. By performing the ROC analysis, we found that T2*L was the 
most useful diagnostic finding for discriminating patients with MSA from those with PD 
or PSP and from healthy control. Variations in the AUC values among the 4 examiners 
were smallest in T2*L. According to the Kendall coefficient of concordance, inter-rater 
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reliability was highest in T2*L. These results suggest that T2*L is useful for any 
examiner when making a diagnosis. 
 
The ROC analysis performed in this study revealed that the AUC value for T2H and 
putaminal atrophy were relatively high (0.618-0.726 and 0.614-0.728, respectively) for 
discriminating patients with MSA from those with PSP or PD and from healthy controls. 
The Kendall coefficient of concordance showed a good inter-rater reliability for T2H and 
putaminal atrophy. T2H observed in MSA is considered as a change, reflecting tissue 
rarefaction associated with neuronal loss and gliosis [15]. Previous reports described the 
clinical usefulness of T2H for differentiating patients with MSA from those with PD and 
from healthy controls [6]; the combination of T2H and T2L within the putamen was a 
specific finding in patients with MSA [16]. In contrast, another study showed that T2H 
was also observed in healthy control subjects on 3-T MRI [17] and even on 1.5-T MRI 
[18]. T2H in patients with MSA was located predominantly at the posterolateral aspect of 
the putamen and was associated with putaminal atrophy [18]. Considering these findings, 
T2H is a useful finding for differentiating patients with MSA from those with PD or PSP 
and from healthy controls, especially when used in combination with other findings such 
as T2L and putaminal atrophy. Similarly, in our study, the AUC value of T2H was 
relatively high, but lower than that of T2*L, and the variability among the 4 examiners in 
evaluating T2H was higher than that for T2*L. The AUC value of putaminal atrophy for 
differentiating patients with MSA from those with PD or PSP and from healthy controls 
was lower than that for T2*L, which varied among the 4 examiners. The reason for this 
variability is assumed that we assessed putaminal atrophy by evaluating the posterolateral 
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linearization of the putaminal margin in visual inspection. Although volumetric analysis 
is presumably accurate for evaluating atrophy, we used visual inspection to know the 
usefulness in the situation of daily clinical practice. 
 
T2*L and T2L observed in the posterolateral part of the putamen in patients with MSA 
presumably reflects pathological iron deposition [15]. T2*-weighted gradient echo 
sequences are superior in detecting iron deposition because of its sensitivity for magnetic 
susceptibility changes. Moreover, in the present study, the AUC value for differentiating 
patients with MSA from those with PD or PSP and from healthy controls was higher in 
T2*L than in T2L.  
 
In previous studies [19, 20], an increased putaminal iron content was reported in 
patients with PD and PSP, as well as in normal aging individuals. Our study and others [8, 
21] showed that T2*L is useful for differentiating patients with MSA from those with PD 
and from healthy controls. However, these previous studies did not consider the 
usefulness for differentiating patients with MSA from those with PSP. In our study, the 
AUC value of T2*L for differentiating patients with MSA from those with PSP and those 
with MSA-P and PSP was 0.797 and 0.852, respectively; these AUC values were lower 
than those for differentiating patients with PD from healthy control subjects. Taking into 
account the quantitative assessment of putaminal iron deposition, a previous study that 
used susceptibility-weighted imaging filtered-phase images revealed that the average 
values (phase shift) of total iron deposition in the putamen were higher in the PSP group 
than in the healthy control group. Furthermore, they were higher in the MSA group than 
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in the PSP, PD, and healthy control groups [22]. In addition, a previous report of 
quantitative assessment of iron content using the transverse relaxation rate (R2*) values 
indicated that patients with MSA-P had higher R2* values in the putamen than those with 
PD and control/s (p < 0.001). Patients with PSP also had higher R2* values in the 
putamen than those with PD and controls, although these differences were not 
statistically significant [23]. Considering the findings described in these reports and in 
our study, pathological iron accumulations in the putamen occur to some extent in 
patients with PSP and these changes are more severe in MSA-P than PSP with 
comparable disease durations. 
 
There are several limitations to the present study. First, the patients received clinical 
diagnoses that were not confirmed pathologically. Second, there were a limited number of 
patients and healthy subjects recruited for this study. Third, we assessed only the signs of 
conventional MRI. The usefulness of diffusion tensor imaging [24], voxel-based 
morphometry [25], and magnetic resonance spectroscopic imaging [26] have been 
reported, and these advanced techniques show superior sensitivity than conventional MRI. 
However, these techniques are limited by relatively long measurement protocols and 
post-processing procedures.  
 
Our study showed that the AUC value of T2*L for differentiating patients with MSA 
from those with PD or PSP and from healthy control subjects, which was the most 
important finding and showed the least variation among the 4 examiners. The inter-rater 
reliability was the highest for T2*L. Therefore, T2*L is currently the most useful and 
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feasible sign for diagnosing MSA in daily clinical practice. 
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Table 1: Demographic data of subjects 
  
MSA 
(n=15) 
PD 
(n=16) 
PSP 
(n=9) 
HC 
(n=10) 
Age (y) 65.5±7.9 66.1±8.6 73.1±7.2 72.5±6.9 
Sex (M/F) 5：10 9：7 7：2 5：5 
Duration of disease (y) 3.3±1.5 7.5±6.6
a
 2.3±0.8   
     
a 
Significantly higher than MSA and PSP (p=0.03 and 0.018, <0.05) 
MSA: Multiple system atrophy, PD: Parkinson's disease, PSP: progressive supra nuclear palsy, 
HC: healthy control subjects 
 
Table 2: Putaminal abnormality scores on visual analog scale in MSA, PD, and PSP 
patients, and in healthy controls 
  MSA (n=15) PD (n=16) PSP (n=9) HC (n=10) 
T2H, mm 17.9 (12.5)
a
 5.9 (4.0) 10.6 (6.0) 7.5 (4.5) 
T2L, mm 13.5 (9.0)
a
 4.3 (3.0) 7.0 (5.5) 6.9 (5.0) 
T2*H, mm 21.0 (19.0)
b
 15.2 (6.5) 14.6 (8.0) 12.0 (6.0) 
T2*L, mm 29.5 (33.0)
a
 6.7 (3.5) 12.1 (8.0) 5.5 (4.0) 
Atrophy, mm 20.1 (21.5)
a
 6.0 (4.0) 10.7 (6.5) 7.4 (6.0) 
Data shown are average (median values; max: 50). 0 indicates absolutely normal, 25 
indicates equivocal, and 50 indicates absolutely abnormal.  
 
T2H: high-intensity signals along the lateral putamen on T2WI, T2L: low-intensity 
signals within the putamen on T2WI, T2*H: high-intensity signals along the lateral 
putamen on T2*WI, T2*L: low-intensity signals within the putamen on T2*WI, 
Atrophy: putaminal atrophy 
MSA: Multiple system atrophy, PD: Parkinson's disease, PSP: progressive supranuclear 
palsy, HC: healthy control subjects 
a
 Significantly higher than PD, PSP, and HC (p<0.05) 
b
 Significantly higher than HC (p<0.05) 
 
  
  15 
Table 3: AUC of putaminal abnormalities in differentiating patients with MSA from 
those with PD or PSP, and from healthy controls, and in differentiating patients 
with MSA-P from those with PD or PSP and healthy controls 
 
  T2H T2L T2*H T2*L Atrophy 
MSA from PD 0.726±0.060 0.731±0.090 0.585±0.066 0.867±0.025 0.728±0.066 
MSA from PSP 0.618±0.076 0.601±0.142 0.597±0.033 0.797±0.033 0.614±0.085 
MSA from HC 0.682±0.028 0.624±0.120 0.639±0.047 0.896±0.041 0.696±0.049 
            
  T2H T2L T2*H T2*L Atrophy 
MSA-P from PD 0.805±0.034 0.775±0.064 0.599±0.061 0.900±0.029 0.851±0.070 
MSA-P from PSP 0.735±0.052 0.665±0.138 0.594±0.024 0.852±0.021 0.775±0.088 
MSA-P from HC 0.772±0.012 0.686±0.122 0.636±0.066 0.915±0.047 0.842±0.076 
      
AUC: the area under the receiver operating characteristic curve 
T2H: high-intensity signals along the lateral putamen on T2WI, T2L: low-intensity signals within 
the putamen on T2WI, T2*H: high-intensity signals along the lateral putamen on T2*WI, T2*L: 
low-intensity signals within the putamen on T2*WI, Atrophy: putaminal atrophy 
MSA: Multiple system atrophy, PD: Parkinson's disease, PSP: progressive supra nuclear palsy, 
HC: healthy control subjects 
 
Table 4: Kendall coefficient of concordance (W) and associated p values for 
the order of ratings for each putaminal finding across the four examiners 
  Kendall W 
  Putaminal sign W value p value 
  T2H 0.6337 < 0.01 
  T2L 0.4950 < 0.01 
  T2*H 0.7696 < 0.01 
  T2*L 0.7959 < 0.01 
  Atrophy 0.6516 < 0.01 
  
     T2H, high-intensity signals along the lateral putamen on T2WI; T2L, low-intensity 
signals within the putamen on T2WI; T2*H, high-intensity signals along the lateral 
putamen on T2*WI; T2*L, low-intensity signals within the putamen on T2*WI; 
Atrophy, putaminal atrophy 
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Fig.1 Putaminal changes in patients with MSA 
A T2-weighted axial image of a patient with MSA-P shows high-intensity signals along 
the lateral margin of the putamen (A, black arrows), low-intensity signals within the 
putamen (A, white arrowheads), and putaminal atrophy (A). A T2*-weighted axial image 
of the same patient also shows low-intensity signals in the posterolateral putamen (B, 
black arrows) and high-intensity signals along the lateral margin of the putamen (B, white 
arrowheads). Although a T2-weighted axial image of a patient with MSA-P shows no 
abnormalities within and around the putamen (C), a T2*-weighted axial image of the 
same patient shows low-intensity signals in the posterolateral putamen (D, black arrows). 
T2-weighted and T2*-weighted axial images of a healthy control subject show no 
abnormalities within and around the putamen (E and F) 
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